Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions DOI Creative Commons

A Glässner,

Diana Dubrall,

Gerda Wurpts

et al.

Frontiers in Allergy, Journal Year: 2025, Volume and Issue: 6

Published: March 27, 2025

Introduction Cefuroxime allergy may present as a delayed-type reaction or an immunoglobulin (Ig)E-mediated immediate-type anaphylactic reaction. The basophil activation test (BAT) is diagnostic tool for cefuroxime-induced reactions, whereas the lymphocyte transformation (LTT) typically applied in drug allergy. This study aimed to compare results of BAT and LTT 15 patients with reactions considered confirmed. pharmacoepidemiological part analyze spontaneous reports cefuroxime-associated European adverse database (EudraVigilance). Methods In EudraVigilance, 668 Economic Area (EEA) between 2010 2023 were analyzed, 182 (27.2%) these originating from Germany. performed according standard protocols. Except one patient, all prior skin tests, thereafter. Results Almost classified serious (EEA, 99.3%; Germany, 98.9%). 60.8% 66.9% (Germany) respective information, occurred after intravenous administration. was 12 (3/12 positive; sensitivity 25%), while (7/15 46.7%). Conclusions Our analysis highlights importance almost serious. Neither negative nor can rule out sensitization reactions.

Language: Английский

Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions DOI Creative Commons

A Glässner,

Diana Dubrall,

Gerda Wurpts

et al.

Frontiers in Allergy, Journal Year: 2025, Volume and Issue: 6

Published: March 27, 2025

Introduction Cefuroxime allergy may present as a delayed-type reaction or an immunoglobulin (Ig)E-mediated immediate-type anaphylactic reaction. The basophil activation test (BAT) is diagnostic tool for cefuroxime-induced reactions, whereas the lymphocyte transformation (LTT) typically applied in drug allergy. This study aimed to compare results of BAT and LTT 15 patients with reactions considered confirmed. pharmacoepidemiological part analyze spontaneous reports cefuroxime-associated European adverse database (EudraVigilance). Methods In EudraVigilance, 668 Economic Area (EEA) between 2010 2023 were analyzed, 182 (27.2%) these originating from Germany. performed according standard protocols. Except one patient, all prior skin tests, thereafter. Results Almost classified serious (EEA, 99.3%; Germany, 98.9%). 60.8% 66.9% (Germany) respective information, occurred after intravenous administration. was 12 (3/12 positive; sensitivity 25%), while (7/15 46.7%). Conclusions Our analysis highlights importance almost serious. Neither negative nor can rule out sensitization reactions.

Language: Английский

Citations

0